Text this: BLINATUMOMAB BRIDGING THERAPY FOR EFFECTIVE MANAGEMENT OF MRD IN PRO-B ALL WITH CNS INVOLVEMENT: A CASE REPORT OF POST TRANSPLANT PATIENT AT 23 MONTHS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION